About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker VRTX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026Evaluation of Pain Treatment After Total Knee Arthroplasty
NCT07538570 · Pain
Suzetrigine, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 4Completed
was active, not recruiting
66Oct 12, 2026Registry ↗
Nov 12, 2026Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Dise…
NCT06747572 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VRTX
Vertex Pharmaceuticals Incorporated
—Active, not recruiting401Dec 31, 2026Registry ↗
Oct 30, 2026Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
NCT07868926 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
14C-VX-407
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Recruiting
was not yet recruiting
8Dec 15, 2026Registry ↗
Oct 30, 2026Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membr…
NCT07204275 · Primary Membranous Nephropathy
Povetacicept, Tacrolimus
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2/3Recruiting176Dec 29, 2028Registry ↗
Oct 30, 2026Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Pain…
NCT06696443 · Diabetic Peripheral Neuropathic Pain
Suzetrigine
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Active, not recruiting455Jan 25, 2027Registry ↗
Oct 29, 2026A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702 · Myasthenia Gravis, Generalized
Povetacicept, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2Active, not recruiting
was recruiting
34Mar 2, 2029Registry ↗
Oct 27, 2026A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation
NCT07813039 · Cystic Fibrosis
VX-581
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Active, not recruiting16Oct 27, 2026Registry ↗
Oct 27, 2026Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in S…
NCT05331183 · Cystic Fibrosis
ELX/TEZ/IVA, IVA
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Active, not recruiting297Apr 6, 2027Registry ↗
Oct 26, 2026Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinu…
NCT05312879 · Proteinuric Kidney Disease
VX-147, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2/3Active, not recruiting522Jun 2, 2028Registry ↗
Oct 22, 2026A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compare…
NCT07890909 · Immunoglobulin A Nephropathy
Povetacicept, Sibeprenlimab
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Not yet recruiting40Dec 12, 2027Registry ↗
Oct 19, 2026A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A…
NCT07807995 · Immunoglobulin A Nephropathy
Povetacicept
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Enrolling by invitation605Dec 28, 2029Registry ↗
Oct 19, 2026Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
NCT07283770 · Cystic Fibrosis
VX-581, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Recruiting152Jul 12, 2027Registry ↗
Oct 15, 2026Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuro…
NCT06628908 · Diabetic Peripheral Neuropathic Pain
Suzetrigine, Placebo (matched to SUZ)
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Recruiting1,100May 31, 2027Registry ↗
Oct 15, 2026Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 1…
NCT05882357 · Cystic Fibrosis
ELX/TEZ/IVA, IVA
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Completed67Sep 4, 2025Registry ↗
Oct 14, 2026A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
NCT06926621 · Myotonic Dystrophy Type 1 (DM1)
VX-670
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2Enrolling by invitation44Jan 30, 2029Registry ↗
Oct 9, 2026A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT05791201 · Type 1 Diabetes
VX-264
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1/2Active, not recruiting7Mar 12, 2027Registry ↗
Oct 9, 2026A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741 · Cystic Fibrosis
VX-522 mRNA therapy, IVA
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1/2Completed26Apr 21, 2026Registry ↗
Oct 9, 2026A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257 · Cystic Fibrosis
VX-121/TEZ/D-IVA
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Active, not recruiting822Oct 30, 2026Registry ↗
Sep 30, 2026Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
NCT07792408 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VX-407, LNG/EE
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Recruiting148Mar 11, 2027Registry ↗
Sep 23, 2026Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
NCT07437105 · Cystic Fibrosis
VX-272, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Recruiting160Jun 26, 2027Registry ↗
Sep 21, 2026Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VX-407
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2Active, not recruiting26Jul 22, 2027Registry ↗
Sep 16, 2026A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
NCT03745287 · Sickle Cell Disease, Hematological Diseases
Exa-cel
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2/3Completed63Jul 7, 2025Registry ↗
Sep 9, 2026Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
NCT07378865 · Pain
Suzetrigine
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Completed13Aug 17, 2026Registry ↗
Sep 1, 2026A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262 · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness
VX-880, VX-017
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Recruiting57Dec 31, 2027Registry ↗
Aug 20, 2026Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidit…
NCT06794996 · Proteinuric Kidney Disease
Inaxaplin
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2Completed42Jul 20, 2026Registry ↗
Aug 20, 2026A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
NCT06185764 · Myotonic Dystrophy Type 1 (DM1)
VX-670, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1/2Active, not recruiting47Feb 2, 2027Registry ↗
Aug 18, 2026Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
NCT07570069 · Pain
Suzetrigine, Efavirenz
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Completed18Jul 16, 2026Registry ↗
Aug 11, 2026A Long-term Follow-up Study in Participants Who Received CTX001
NCT04208529 · Beta-Thalassemia, Thalassemia
CTX001
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Enrolling by invitation160Sep 30, 2039Registry ↗
Aug 10, 2026Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
NCT06154447 · Cystic Fibrosis
VX-828, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Completed165Jul 10, 2026Registry ↗
Jul 20, 2026Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral…
NCT07231419 · Diabetic Peripheral Neuropathic Pain
Suzetrigine, Placebo (matched to SUZ)
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Recruiting734Apr 6, 2027Registry ↗
Jul 1, 2026Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-…
NCT05356195 · Beta-Thalassemia, Thalassemia
CTX001
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Active, not recruiting16Nov 14, 2027Registry ↗
Jul 1, 2026Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disea…
NCT05329649 · Sickle Cell Disease, Hydroxyurea Failure
CTX001
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Active, not recruiting13Jun 6, 2027Registry ↗
Jun 8, 2026A Phase 1, First-in-human Study of VX-433
NCT07584434 · Narcolepsy Type 1 (NT1)
VX-433, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Recruiting118Mar 5, 2027Registry ↗
Jun 5, 2026Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Month…
NCT06460506 · Cystic Fibrosis
ELX/TEZ/IVA, IVA
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Active, not recruiting50Sep 30, 2027Registry ↗
Jun 1, 2026Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860 · Diabetic Peripheral Neuropathic Pain
VX-993, Pregabalin
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2Recruiting300Mar 25, 2027Registry ↗
May 28, 2026A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
NCT06619847 · Acute Pain
VX-993, HB/APAP
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2Completed367May 27, 2025Registry ↗
May 28, 2026Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Yea…
NCT05422222 · Cystic Fibrosis
VX-121/TEZ/D-IVA
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Active, not recruiting210Jun 30, 2030Registry ↗
Apr 29, 2026Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibro…
NCT05844449 · Cystic Fibrosis
VNZ/TEZ/D-IVA
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Enrolling by invitation174Jul 30, 2029Registry ↗
Apr 2, 2026Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy…
NCT07349394 · Cystic Fibrosis
VNZ/TEZ/D-IVA, Rosuvastatin
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Completed18Feb 28, 2026Registry ↗
Mar 30, 2026Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
NCT07074327 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VX-407, LNG/EE
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Completed74Feb 20, 2026Registry ↗
Mar 27, 2026A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Particip…
NCT07022119 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VX-407, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 1Completed32Feb 24, 2026Registry ↗
Mar 25, 2026Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Ce…
NCT05951205 · Sickle Cell Disease
Exa-cel
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Withdrawn0Dec 31, 2033Registry ↗
Mar 23, 2026An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a K…
NCT06832410 · Type 1 Diabetes, Kidney Transplant
Biological/Vaccine
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Recruiting10Sep 17, 2026Registry ↗
Mar 23, 2026Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Depen…
NCT05477563 · Beta-Thalassemia, Thalassemia
CTX001
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Recruiting26Jun 9, 2027Registry ↗
Mar 3, 2026Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Y…
NCT05153317 · Cystic Fibrosis
ELX/TEZ/IVA, IVA
VRTX
Vertex Pharmaceuticals Incorporated
Phase 3Completed71Jan 29, 2026Registry ↗
Dec 31, 2025Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT06506773 · Cystic Fibrosis
VRTX
Vertex Pharmaceuticals Incorporated
—Completed79Nov 27, 2025Registry ↗
Dec 17, 2025A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalasse…
NCT03655678 · Beta-Thalassemia, Thalassemia
CTX001
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2/3Completed59Nov 13, 2025Registry ↗
Dec 15, 2025A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain Afte…
NCT06887972 · Acute Pain
Suzetrigine
VRTX
Vertex Pharmaceuticals Incorporated
Phase 4Completed100Oct 24, 2025Registry ↗
Dec 15, 2025A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain Afte…
NCT06887959 · Acute Pain
Suzetrigine
VRTX
Vertex Pharmaceuticals Incorporated
Phase 4Completed47Oct 27, 2025Registry ↗
Oct 1, 2025Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
NCT06176196 · Painful Lumbosacral Radiculopathy
VX-548, Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Phase 2Completed218Oct 2, 2024Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:32 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances